RESUMO
INTRODUCTION: This phase II trial was conducted to assess the efficacy and safety of 10-Ethyl-10-Deaza-Aminopterin (10-EDAM), a folate antagonist, in metastatic breast cancer patients who had received no more than one prior chemotherapy regimen. METHODS: Fifty-five patients were treated on an initial weekly dose 80 mg/m(2) of 10-EDAM. Patients who had received a prior chemotherapy regimen in the adjuvant setting (group 1) were considered separately from patients who had received a prior chemotherapy regimen in the metastatic setting (group 2). RESULTS: The response rate for both groups combined was 18%, and median time to progression was 3 months. Median overall survival was 12 months. Treatment was associated with common chemotherapy-related toxicities, such as 25% grade three or four neutropenia and 20% grade three or four stomatitis. CONCLUSION: In patients with metastatic breast cancer who had received one prior chemotherapy regimen, 10-EDAM was well tolerated. In general, while definite antitumor activity was documented, time to progression was brief.
Assuntos
Aminopterina/análogos & derivados , Antineoplásicos/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Adulto , Idoso , Agranulocitose/induzido quimicamente , Alopecia/induzido quimicamente , Aminopterina/efeitos adversos , Aminopterina/uso terapêutico , Anemia/induzido quimicamente , Antineoplásicos/efeitos adversos , Neoplasias da Mama/secundário , Progressão da Doença , Feminino , Humanos , Leucopenia/induzido quimicamente , Pessoa de Meia-Idade , Náusea/induzido quimicamente , Análise de Sobrevida , Fatores de Tempo , Resultado do TratamentoAssuntos
Acarbose/uso terapêutico , Doenças Cardiovasculares/prevenção & controle , Diabetes Mellitus Tipo 2/tratamento farmacológico , Hipertensão/prevenção & controle , Hipoglicemiantes/uso terapêutico , Doenças Cardiovasculares/epidemiologia , Diabetes Mellitus Tipo 2/complicações , Intolerância à Glucose/tratamento farmacológico , Glibureto/uso terapêutico , Humanos , Hipertensão/complicações , RiscoRESUMO
OBJECTIVES: Calcitonin (CT) has a regulative function in calcium (Ca) transfer from mother to the fetus. There are indications that cholecalciferol can play a role in this process. With this background, the effect of 24, 25-dihydroxycholecalciferol (24, 25-DHC) on immunoreactive CT by human placenta at term was studied in vitro. METHODS: Placental tissue samples were incubated in culture medium with normal total Ca (1.3 mM) concentrations during 6 hours at 37 degrees C. 24, 25-DHC was added to the samples. RESULTS: Addition of 24, 25-DHC in concentrations of 25, 75 and 150 pg/ml was followed by a significant decrease of CT levels in medium. The concentrations decreased from 100% (basis value after 2 hours) to 31%, 46% and 49% respectively. CONCLUSION: Probably 24, 25-DHC has a modulating effect on the regulation of placental Ca transfer by CT.
